Literature DB >> 621753

Chemotherapeutic activity of new 2-chloroethylnitrosoureas in rat L5222 leukemia: comparison of bifunctional and water-soluble derivatives with 1,3-bis(2-chloroethyl)-1-nitrosourea.

W J Zeller, G Eisenbrand, H H Fiebig.   

Abstract

The chemotherapeutic activity of eight nitrosourea derivatives was compared with that of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in transplantable rat leukemia L5222 cells. Bifunctional 1,1'-polymethylenebis-3-(2-chloroethyl)-3-nitrosoureas effected cure rates between 30 and 75% in single equitoxic doses in the therapy of advanced ip implanted L5222 [staging of L5222 leukemia development (hr before median day of death in controls): early = greater than 120; advanced = 120--61; late = 60--25; and preterminal = 24--0]. Of three water-soluble monofunctional alkylating 1-(omega-hydroxyalkyl)-3-nitrosoureas, 1-(2-hydroxyethyl)-3-(2-chloroethyl)-3-nitrosourea yielded more cures (90%) than did BCNU (cure rate, 70%) and was also superior to the other substances. Against preterminal ip implanted and late intracerebrally implanted L5222, the hydroxyethyl compound was significantly superior to BCNU.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621753     DOI: 10.1093/jnci/60.2.345

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  13 in total

1.  Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.

Authors:  M Poisson; J Chiras; F Fauchon; C Debussche; J Y Delattre
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

Review 2.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Chemotherapy studies in autochthonous rat tumors: carcinomas of the forestomach.

Authors:  M Habs; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

4.  Improved delivery through biological membranes. XLV. Synthesis, physical-chemical evaluation, and brain uptake studies of 2-chloroethyl nitrosourea delivery systems.

Authors:  K Raghavan; T Loftsson; M E Brewster; N Bodor
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

5.  Combination chemotherapy with 5-fluorouracil (5FU) and 1,3-bis(2-chloro-ethyl)-1-nitrosourea (BCNU) prolongs survival of rats with dimethylhydrazine-induced colon cancer.

Authors:  M Danzi; M R Lewin; J P Cruse; C G Clark
Journal:  Gut       Date:  1983-11       Impact factor: 23.059

6.  Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).

Authors:  B Hartley-Asp; P I Christensson; K Gunnarsson; P O Gunnarsson; G Jensen; J Polacek; A Stamvik
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

7.  Examination of four newly synthesized 2-chloroethylnitrosoureas in comparison with BCNU, CCNU, MeCCNU, chlorozotocin and hydroxyethyl-CNU in preterminal rat leukemia L 5222.

Authors:  W J Zeller; G Eisenbrand; H H Fiebig
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

8.  Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.

Authors:  R Osieka; P Glatte; R Pannenbäcker; C G Schmidt
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Brain uptake and CNS levels of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (HECNU).

Authors:  C Unger; H Eibl; J Engel; G A Nagel; G Eisenbrand
Journal:  Invest New Drugs       Date:  1987-12       Impact factor: 3.850

10.  Antineoplastic activity of esters and amides of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-aminoacids.

Authors:  W J Zeller; K Ehresmann; G Eisenbrand
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.